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Abstract
In recent years, innovative treatment for patients with autoimmune and autoinflamma-
tory diseases has advanced in concert with our increased understanding of molecular 
and clinical immunology. Deeper understanding of autoimmunity has allowed for the 
development of cutting-edge biologic drugs for patients with relatively common autoim-
mune diseases. During this same period, knowledge regarding the molecular bases of 
autoinflammatory genetic diseases has also greatly expanded. Biologic immunothera-
peutic agents developed for autoimmune diseases that primarily target cytokines that 
are also dysregulated in the uncommon autoinflammatory diseases are the focus of 
this article. In the following pages, selected genetic autoinflammatory diseases and key 
immunotherapeutic treatment approaches are addressed. The current understanding of 
these diseases and mechanisms by which therapeutic agents may benefit patients are 
reviewed. Indications, risks, and additional considerations for the use of these agents in 
treatment of autoinflammatory disorders are addressed as well.
Keywords: biologic agents, autoinflammatory diseases, cytokines, inflammasome, IL-1, 
TNF, IL-6, interferon
1. Introduction
Over the past 20 years, scientific work that uncovered the genetic basis of autoinflammatory 
diseases (AutoIDx) has expanded knowledge about pathways of the innate system. Important 
discoveries have linked autoinflammation to defects in the innate immune system and autoim-
munity largely to changes in adaptive immune function. Immunotherapeutic agents which tar-
get cells, cytokines, and mediators of immunologic responses are part of our current “toolbox” 
to treat autoimmune diseases. These pharmacological agents also target and treat the excess 
downstream inflammatory mediators produced by genetic mutations in the innate immune 
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system that cause the syndromes identified as AutoIDx. This review addresses key immuno-
therapeutic biologic approaches for treating selected AutoIDx. Current therapeutic approaches, 
as well as risks and additional considerations in the use of these agents, are addressed.
2. Innate and adaptive immunity
The innate and adaptive immune systems normally work together in integrated fashion uti-
lizing antigen-specific and antigen-independent mechanisms. The host’s first line of defense 
is the innate system which recognizes nonspecific immunologic signals and then directs fur-
ther innate system activities in concert with the adaptive immune system. In this way, the 
extent and complexity of the overall immunologic response is enhanced. Genetic defects in 
the function and control of the innate immune system cause the AutoIDx. These disorders 
produce unprovoked, often self-limited episodic inflammation that is not associated with 
antigen-specific T cell reactions or with autoantibody production. AutoIDx have no associa-
tion with specific Major histocompatibility complex (MHC) alleles, unlike autoimmune dis-
eases. Research and newer genetic techniques as exemplified by next-generation sequencing 
have uncovered the etiologies of multiple AutoIDx, although mutations underlying some 
AutoIDx remain unknown. Each discovery has furthered our understanding of pathways and 
therapeutic targets in the innate immune system [1].
The innate immune system is composed of effector cells, such as activated macrophages, as 
well as receptors, cytokines, and downstream response proteins. Surface pattern recogni-
tion receptors including Toll-like receptors (TLRs) and pathogen-associated molecular pat-
terns (PAMPS) can activate inflammasome assembly through effects on NF-κB production 
and subsequent immunological signaling (Signal 1 activation). Molecules such as crystals 
in gout, heat-shock proteins, damaged tissue (such as with burns), as well as other PAMPS 
and damage-associated molecular patterns (DAMPS) (Signal 2 activation) can also provoke 
this response. Following Signal 1 and 2 triggers, intracellular pattern recognition proteins, 
including nucleotide-binding oligomerization domain-like receptors (NOD-like receptors, 
NLRs such as NOD-like receptor P3 (NLRP3), and NOD-like receptor C4 (NLRC4)) and cyto-
plasmic DNA receptors [2], are then activated. Cytoplasmic NLRs oligomerize in response 
to these initial signals, forming inflammasomes that are multimeric scaffolded structures 
that further activate cytokines [3, 4]. Inflammasomes specific to different NLR structures 
perpetuate cascading downstream signals. NLRP3 specifically is associated with apoptosis-
associated speck-like protein containing (ASC) a caspase recruitment domain (CARD) and 
procaspase-1. Inflammasome NLRP3 is key as it leads to production of the central cytokine, 
interleukin (IL)-1, via the caspase-1 activation cascade. This is followed by conversion of 
IL-1β and IL-18 from inactive to enzymatically active proteins (see Figure 1) [5, 6]. Loss-
of-function or gain-of-function gene mutations that code regulatory proteins which control 
inflammasome scaffold formation and subsequent cytokine activity are among the causes of 
AutoIDx.
Unlike AutoIDx, relatively more common autoimmune disorders, including systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA), are largely caused by defective tolerance, 
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but the innate immune system plays a key role as well. Some autoimmune diseases, especially 
early-onset Crohn’s disease (CrD) and sarcoidosis, are caused by innate system dysregulation 
occurring in concert with adaptive immune dysfunction [7]. Autoimmune diseases today are 
regularly treated with pharmaceutical biologic agents that target relevant inflammatory path-
ways. These therapies have changed the lives of the many people affected by such diseases. 
AutoIDx affect fewer individuals, but these populations nonetheless have benefitted from cur-
rent-day immunologic therapeutic discoveries which are the focus of this review (for detailed 
reviews of the adaptive and innate immune systems and autoimmunity, see Refs. [8–12]).
3. Autoinflammatory diseases
The AutoIDx were identified through translational research efforts starting with uncovering the 
genetic cause of familial Mediterranean fever (FMF) [13] followed by identification of genes for 
cryopyrin-associated periodic syndromes (CAPS). AutoIDx may present with typical monthly 
episodes, or may be more unpredictable, with exacerbations no more than 2–3 times per year. 
Typical spells can be set off by seemingly innocuous triggers such as vaccination or cool envi-
ronmental temperature [14]. Each disease has well-characterized features, usually including 
fevers, hence the former term “periodic fever syndromes” (see Tables 1 and 2). Below, repre-
sentative conditions for which biologic therapies have been used are addressed in some detail.
3.1. Cryopyrin-associated periodic syndromes
CAPS are monogenetic dominant disorders due to the defective cold-induced autoinflamma-
tory syndrome 1 (CIAS1) or NLRP3 gene which alters the protein cryopyrin. CAPS exhibit a 
range of severity based on variable penetrance of the mutations: familial cold autoinflammatory 
syndrome (FCAS) is the mildest, Muckle-Wells syndrome (MWS) has moderate features, and 
neonatal-onset multisystem inflammatory disease (NOMID, also termed chronic infantile neu-
rological, cutaneous, articular syndrome CINCA) is the most severe and potentially life-threat-
ening disease. Features are usually present in newborns with rash and fever; additionally, 
in MWS and NOMID, arthritis develops. In FCAS a cold environment precipitates exacerba-
tions of symptoms. NOMID may cause severe arthritis with destructive bony overgrowth, as 
well as chronic meningitis and developmental delays. NOMID and MWS may lead to hear-
ing loss; amyloidosis and renal failure develop in 25% of untreated individuals [1, 14].
In CAPS, gain-of-function dominant mutations occur in NLRP3, a member of the NLR protein 
family. Somatic mosaicism may also be associated with typical symptoms. In NOMID sporadic 
mutations are frequent, with up to 40% having no identifiable mutation [1]. In CAPS, spon-
taneous activation of cell surface TLRs and cytoplasmic sensors occurs followed by antigen 
unprovoked assembly of the inflammasome complex. Caspase-1 is then activated and converts 
both pro-IL-1ß and pro-IL-18 to operational cytokines [3, 5]. Excess activity of the assembled 
multimolecular inflammasome results in unregulated production of IL-1ß, causing CAPS. 
Overproduction of IL-1β causes further downstream excess inflammatory responses. If left 
untreated CAPS can lead to increased serum amyloid A (SAA) protein accumulation, amyloido-
sis, and renal failure [1, 14].
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Disease (acronym) Gene; heritance Affected protein
Functional changes
IL-1β activation disorders of the inflammasome
Cryopyrin-associated periodic syndrome
• Familial cold autoinflammatory  
syndrome (FCAS)
• Muckle-Wells syndrome (MWS)
• Neonatal-onset multisystem  
inflammatory disease (NOMID)
NLRP3, CIAS1 (1q44); AD Cryopyrin NALP3/PYPAF1
Inflammasome activation
Excess IL-1β production
Deficiency of the interleukin-1 receptor 
antagonist (DIRA)
IL-1RN (2q14.2); AR Lack of IL-1Ra
Unopposed IL-1 signaling
NOD-like receptor C4-MAS NLRC4; AD IL-1β and IL-18 produced
Macrophage activation
Familial Mediterranean fever (FMF) MEFV (16p13.3); AR (AD) Defective pyrin (marenostrin)
Increased IL-1 activation
Hypergammaglobulinemia D syndrome  
(HIDS)
MVK (12p24); AR Defective mevalonate kinase
IL-1β dysregulation
Pyogenic arthritis, pyoderma gangrenosum,  
and acne (PAPA)
PSTPIP1 (15q24-25.1); AD PSTPIP1 dysfunction
Cytoskeletal changes stimulates 
inflammasome
TNF disorders of the innate immune system
TNF receptor-associated periodic syndrome 
(TRAPS)
TNFRSF1A (12p13); AD Mutant TNF receptor activates 
Inflammation via Il-1
Deficiency of adenosine deaminase (DADA) CERC1; AR Lack of activity of ADA2
Stimulate TNF dysregulation
Interferon activation disorders
STING-associated vasculopathy of infancy 
(SAVI)
TMEM173; AD STING activation
Increased IFN-β transcription
Chronic atypical neutrophilic dermatosis 
with lipodystrophy and elevated temperature 
(CANDLE)
PSMB8; AR Proteasome dysfunction
Induced IFN response genes
AD, autosomal dominant; ADA, adenosine deaminase; AR, autosomal recessive; CANDLE, chronic atypical neutrophilic 
dermatosis with lipodystrophy/elevated temperature; CAPS, cryopyrin-associated periodic syndromes; CNS, central 
nervous system; DADA2, deficiency of adenosine deaminase 2; DIRA, deficiency of the IL-1 receptor antagonist; 
FCAS, familial cold autoinflammatory syndrome; FMF, familial Mediterranean fever; HIDS, hyper-IgD syndrome; 
IFN, interferon; IL-1, interleukin-1; ILD, interstitial lung disease; JAK, Janus kinase; MAB, monoclonal antibody; 
MAS, macrophage activation syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NLRC4, 
NOD-like receptor C4; NOMID, neonatal-onset multisystem inflammatory disease; NR, not reported; PAPA, pyogenic 
arthritis, pyoderma gangrenosum, and acne; SAVI, STING-associated vasculopathy with onset in infancy; TNF, tumor 
necrosis factor; TRAPS, TNF receptor-associated periodic syndrome
Table 1. Classification of selected autoinflammatory disease (adapted from Refs. [15–17]).
Immunotherapy - Myths, Reality, Ideas, Future274
3.2. Deficiency of the IL-1 receptor antagonist (DIRA)
The naturally occurring protein, “IL-1 receptor antagonist,” attenuates downstream activation of 
IL-1 produced by normal function of the inflammasome. Loss-of-function gene mutations cause 
DIRA due to dysfunctional IL-1 receptor binding to this defective protein which normally would 
prevent dampening of IL-1 activity [3]. DIRA differs from CAPS possibly due to uninterrupted 
Ethnicity Duration of 
episodes
Clinical features Amyloid
FMF Arab, Turkish, Jewish, 
Armenian
1–3 days Erysipeloid rash,
serositis, peritonitis,
episodic inflammatory 
arthritis
Variable; significant 
risk
TRAPS No specific group >7–10 days Rash, myalgia, serositis, 
arthritis, conjunctivitis, 
periorbital edema
10%
HIDS Dutch, French, other 
Europeans
3–7 days Maculopapular rash,
abdominal pain, diarrhea,
polyarthritis, ulcers, 
adenopathy
Rare
CAPS: FCAS Mainly European Often <24 h Cold triggered urticarial-like 
rash; nausea; arthralgia
Uncommon
CAPS: MWS Northern European 2–3 days Urticarial-like rash, arthritis, 
conjunctivitis, hearing loss
Up to 25%
CAPS: NOMID No specific group Continuous with 
flares
Urticarial-like rash, chronic 
arthritis and overgrowth, 
uveitis, meningitis, 
developmental delay
Up to 25%
PAPA NR Early joints; later 
skin lesions
Fever, sterile arthritis, skin 
ulcerations, pyoderma 
gangrenosum, severe cystic 
acne
NR
DIRA Lebanon, Brazil, 
Turkey, and others
Continuous from 
onset
Fever, pustular neutrophilic 
dermatitis, aseptic osteitis
NR
SAVI NR Continuous from 
onset
Fever, ischemic skin, digital 
necrosis, arthritis, myositis, 
ILD
NR
AD, autosomal dominant; ADA, adenosine deaminase; AR, autosomal recessive; CANDLE, chronic atypical neutrophilic 
dermatosis with lipodystrophy/elevated temperature; CAPS, cryopyrin-associated periodic syndromes; CNS, central 
nervous system; DADA2, deficiency of adenosine deaminase 2; DIRA, deficiency of the IL-1 receptor antagonist; 
FCAS, familial cold autoinflammatory syndrome; FMF, familial Mediterranean fever; HIDS, hyper-IgD syndrome; 
IFN, interferon; IL-1, interleukin-1; ILD, interstitial lung disease; JAK, Janus kinase; MAB, monoclonal antibody; 
MAS, macrophage activation syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NLRC4, 
NOD-like receptor C4; NOMID, neonatal-onset multisystem inflammatory disease; NR, not reported; PAPA, pyogenic 
arthritis, pyoderma gangrenosum, and acne; SAVI, STING-associated vasculopathy with onset in infancy; TNF, tumor 
necrosis factor; TRAPS, TNF receptor-associated periodic syndrome
Table 2. Features of selected autoinflammatory diseases (adapted from Refs. [15, 17]).
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overactivity of both IL-1β and IL-1α in DIRA. Presentation during the newborn period is typical 
with fever, skin pustulosis, with neutrophilic infiltrates, and a characteristic pattern of osteitis of 
ribs, clavicles, vertebrae, and hips. If the excess cytokine levels are untreated in DIRA patients, 
there is significant morbidity and mortality due to uncontrolled IL-1 effects [16].
3.3. NLRC4-related macrophage activation syndrome (MAS)
Inflammasome dysregulation from a mutation in NOD-like receptor C4 (NLRC4) causes 
NLRC4-MAS. Analysis shows spontaneous inflammasome operability and activation of cap-
sace-1 causing deregulated release of IL-1β as well as production of extremely high levels of 
IL-18. Fever, colitis, arthralgias, and life-threatening MAS, similar to systemic juvenile idio-
pathic arthritis (JIA), develop in these children [4, 18]. In MAS, presentation includes coagulopa-
thy, pancytopenia, and hyperferritinemia, with significant morbidity and mortality. Extremely 
high levels of IL-18 are characteristic of this disorder but not CAPS. Anti-IL-1 therapies are 
currently on the market, but there are no available anti-IL-18 blockers, a limitation in optimally 
treating this disorder.
3.4. TNF receptor-associated periodic syndrome
TNF receptor-associated periodic syndrome (TRAPS) is due to dominant mutations in the 
TNFRSF1A gene [14, 19]. Irregular 2–4 week cycles occur 2–6 times a year [20, 21]. Symptoms 
include fever, rash, periorbital swelling, arthritis, and conjunctivitis. Serositis, similar to FMF, 
is reported, but in contrast, renal failure due to amyloidosis is uncommon.
Pathogenesis appears to be due to varying mutational effects on the activation of NF-κB (Signal 1) 
and caspace which each cause increased cytokine release. NF-κB dysregulation promotes inflam-
mation by inducing cytokine production and also by leading to inflammatory cell apoptosis [16]. 
Unchecked IL-1β release in TRAPS patients is due in part to effects of exaggerated production of 
mitochondrial reactive oxygen species (Signal 2) as well as increased caspace-1 activity. In addi-
tion, impaired mutant TNF receptor shedding occurs. Mutant 55 kDa TNF receptor 1a surface-
based receptors appear to have several defects: abnormal protein-folding responses, binding TNF 
less effectively causing defective TNF-associated apoptosis, prolongation of immune responses to 
non-mutated receptor-bound TNF, and uncontrolled downstream signaling [22]. Abnormal p55 
receptors shed in TRAPS are unable to serve as naturally occurring decoys for circulating TNF 
[20]. These mechanisms suggest benefit of anti-TNF as well as anti-IL-1 approaches [3, 20–25].
3.5. Familial Mediterranean fever
FMF is due to recessive Mediterranean fever gene (MEFV) mutations and is the most common 
AutoIDx. It is characterized by self-limited episodes of fever, serositis, arthritis, and renal fail-
ure due to amyloidosis. It is theorized that pyrin has a role in IL-1 activation by suppressing 
pro-caspase-1 activation possibly through competition for ASC. Defective pyrin does not bind 
normally to ASC, weakening its negative regulator function in NLRP3 inflammasome activa-
tion [16]. Mutations hence cause uncontrolled activation of capsace-1 via the IL-1 inflamma-
some [23, 26]. A unique pyrin-related inflammasome also leads to activation of IL-1 and seems 
to be important in FMF as well [1].
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Colchicine has been a standard FMF treatment since the 1970s. Its mechanism is due to inhi-
bition of both cytoplasmic microtubules and inflammasome activity [27]. Pyrin also binds 
microtubules; this pyrin-like action of colchicine in FMF may explain its efficacy in part [16]. 
About 10% of FMF patients fail colchicine therapy. Given the high morbidity in FMF, alterna-
tive biologic therapies addressing cytokine dysregulation are used in such cases.
3.6. Interferonopathies
A group of AutoIDx related to uncontrolled type I interferon (IFN) activity has been recently 
described including stimulator of IFN genes (STING) associated with vasculopathy of infancy” 
(SAVI)” [1, 2, 28]. Early-onset livedo reticularis, ulcerative skin lesions, pulmonary symptoms, 
and Raynaud’s disease with vasculopathy are described. SAVI is due to mutations in STING 
transmembrane proteins increasing IFN levels [28]. The abnormal STING induces IFN regula-
tory factor that translocates to nuclei and promotes transcription of IFN [2]. The overproduc-
tion of type I IFN binds to receptors [IFN associated receptor IFNAR-1 or IFNAR-2], leading 
to unchecked protein kinase signaling and increased IFN-induced cytokine release. Targeting 
this pathway may be effective for SAVI and other interferon-driven inflammatory diseases, 
such as SLE, a more common primarily autoimmune disorder [1].
4. Immunotherapeutic agents
Early immunologic intervention has evolved from the use of vaccines in the late 1800s to 
administration of intravenous immunoglobulin in the 1980s to current-day immunother-
apeutics. Advances such as production of monoclonal antibodies (MABs) by creation 
of hybridomas and molecular cloning have paralleled our growing understanding of 
immunology. Innovative work identifying receptors and signaling pathways to iden-
tify new therapeutic targets for autoimmunity paralleled the discovery of the genetic 
AutoIDx. Widespread production and utilization of immunotherapeutics are directly 
attributable to these efforts [11, 29–31].
Food and Drug Administration (FDA)-approved medications are regularly tested for appli-
cability for additional disease processes. Therapies marketed for relatively common autoim-
mune diseases, such as RA, are studied as potential treatment of AutoIDx “orphan diseases.” 
The following is a review of selected immunotherapeutic medications used to treat AutoIDx 
based on scientific evidence and immunologic pathways (see Table 3; see Figure 1). Side 
effects, toxicities, and additional considerations with the use of these therapeutic agents are 
also addressed.
4.1. Anti-IL-1 therapy
The central mediator for multiple AutoIDx, IL-1, was one of the first identified cytokines. It 
was termed the “endogenous pyrogen” since fever is one of its main consequences. Inactive 
IL-1β is cleaved to its active form by the IL-1 inflammasome complex. Its naturally occur-
ring receptor antagonist, IL-1Ra, was engineered into an immunotherapeutic, anakinra, and 
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Generic name Brand name Approved indications Type Mechanism of action
Adalimumab Humira RA, Ps, AS, PsA, 
uveitis, CrD, JIA
Human MAB Inhibits TNF-α
Anakinra Kineret RA, CAPS Recombinant protein IL-1 receptor 
antagonist
Canakinumab Ilaris CAPS, JIA Human MAB Inhibits IL-1β
Certolizumab Cimzia RA, AS, PsA, CrD Humanized FAB Inhibits TNF-α
Etanercept Enbrel RA, JIA, Ps, PsA, AS Fusion receptor Soluble TNF-α receptor 
antagonist
Golimumab Simponi RA, Ps, AS, PsA, CrD, 
UC
Human MAB Inhibits TNF-α
Infliximab Remicade RA, AS, PsA, UC, CrD Chimeric MAB Inhibits TNF-α
IFN-β 1a Rebif MS Cytokine inhibitor Targets type 1 IFN
IFN-β 1b Betaseron MS Cytokine inhibitor Targets type 1 IFN
Rilonacept Arcalyst CAPS Fusion receptor Targets IL-1R1/IL-R 
accessory receptor
Tocilizumab Actemra RA, JIA, sJIA Humanized MAB Inhibits IL-6 receptor
Tofacitinib Xeljanz RA Small molecule;
JAK inhibitor
Specifically blocks JAK-
STAT pathway
AS, ankylosing spondylitis; CAPS, cryopyrin associated periodic syndromes; CrD, Crohn’s disease; FAB, antibody 
fragment; IFN, interferon; JAK, Janus kinase; MAB, monoclonal antibody; MS, multiple sclerosis; JIA, juvenile idiopathic 
arthritis; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; sJIA, systemic JIA; SLE, systemic lupus 
erythematosus; TNF, tumor necrosis factor; UC, ulcerative colitis
Table 3. Selected immunotherapeutic agents for autoinflammatory diseases (adapted from Refs. [11, 17]).
approved by the FDA in 2001 for treatment of RA. This agent is a competitive inhibitor of 
IL-1α and IL-1β receptor binding because the drug itself adheres to the receptor but does not 
produce downstream signaling. While its benefit in RA has never been dramatic, anti-IL-1 
therapy is key in management of CAPS as well as other AutoIDx. Three anti-IL-1 agents are 
FDA approved and used in CAPS. Approved in 2009, canakinumab is a MAB to IL-1β with a 
long half-life that enables dosing every 1–2 months. Rilonacept is a fusion protein made from 
IL-1R accessory protein linked to the Fc portion of an IgG1 molecule which inhibits IL-1β and 
downstream signaling. It also acts as a soluble decoy for IL-1α, also preventing this cytokine 
from binding with the receptor. These agents control FCAS and MWS and are partly benefi-
cial in NOMID [32–37].
Dysregulation of IL-1 as a key mediator is important in other disorders including systemic JIA 
and adult-onset Still’s disease (AOSD) [38–40]. These diseases are also thought to be part of the 
spectrum of AutoIDx and respond well, sometimes dramatically, to anti-IL-1 agents. Given the 
presence of MAS and similarity to systemic JIA, NLRC4-MAS has been treated and responds, 
at least in part, to anti-IL-1 therapy [1, 3, 41]. The predominance of high IL-18 levels, which are 
not diminished with this approach, may explain the partial response to anti-IL-1 treatment. 
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Unfortunately, no anti-IL-18 agents are currently marketed although efforts to develop such 
agents are underway. In DIRA, excessive IL-1β and IL-1α are both released. Based on pathogen-
esis of this disorder, and the understanding that some available agents inhibit both IL-1β and 
IL-1α actions, anti-IL-1 agents have been successfully used in DIRA [16].
In several other AutoIDx, pathogenesis involves activation of the IL-1 inflammasome by 
Signal 2 mechanisms including elevated reactive oxygen species, PAMPS and DAMPs. In 
TRAPS, caspace-1 is activated in vitro even while treated with anti-TNF therapy [23]. Hence, 
anti-IL-1 treatment may be ideal for treating these patients [42]. In FMF, defective pyrin fails 
to suppress inflammasome behavior, and pro-IL-1 is increasingly activated. Reports detail 
response to anti-IL-1 therapy in FMF [6, 14, 43]. All these observations confirm response to 
anti-IL-1 therapy by a spectrum of AutoIDx [3, 21, 25, 43, 44].
Figure 1. Targeted sites for therapeutic agents used in autoinflammatory diseases. Signal 1 inflammasome activation: 
surface pattern recognition receptors such as Toll-like receptors (TLR) and pathogen-associated molecular patterns 
stimulate production of molecules such as NF-κB and activate inflammasome assembly through downstream 
immunologic processes. Signal 2 inflammasome activation: molecules such as crystals in gout, heat-shock proteins, 
or damaged tissue (such as burns) as well as other pathogen-associated molecular patterns and damage-associated 
molecular patterns activate inflammasome assembly through production of reactive oxygen species (ROS) as well as 
downstream immunologic processes. ASC, apoptosis-associated speck protein; ER, endoplasmic reticulum; IFNAR, 
interferon-associated receptor; IFN, interferon; IL-1, interleukin-1; IL-1 R, IL-1 receptor; IL-1Ra, IL-1 receptor antagonist; 
IL-6, interleukin 6; IL-6R, IL-6 receptor; IL-18, interleukin-18; JAK, Janus kinase; NLRP3, NOD-like receptor P3; ROS, 
reactive oxygen species; TLR, Toll-like receptor; TNF, tumor necrosis factor; TNF-R, TNF receptor.
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4.2. Anti-TNF therapy
TNF is part of a superfamily of cytokines that induce necrosis of cancer cells, leading to the 
term “tumor necrosis factor.” TNF-α is present on the surface of cells as a transmembrane pro-
tein, and its cleavage leads to release of soluble TNF-α. Two receptors regulate this cytokine’s 
function – TNF receptor TNFR1 55 kd and TNFR2 75 kd. The 55 kd receptor is membrane 
bound, and upon stimulation by TNF-α, cells release other cytokines such as IL-2 and IFN. 
Extracellular TNFR2 75 kd receptors deactivate soluble TNF, blunting its action. The anti-TNF 
agent, etanercept, an injectable biologic approved for the treatment of RA in 1998 and JIA in 
1999, is an engineered fusion protein comprised of two naturally occurring soluble human 
75-kd TNF receptors linked to an Fc portion of an IgG1. Etanercept mimics the natural recep-
tor by binding extracellular TNF, limiting activation of the inflammatory response. In CrD, 
pathogenesis involves innate immune system activation through membrane-bound TNF. 
Especially in early-onset disease, NOD gene mutations and dysfunctional NF-κB activation 
are also pathogenic [7]. In CrD, etanercept has been found to be less effective likely due to 
the predominance of membrane-bound TNF in this disorder rather than soluble TNF that is 
inhibited by this agent [45]. Differences in receptor localization, binding, and downstream sig-
naling explain therapeutic differences between anti-TNF agents. Infliximab is a chimeric MAB, 
whereas golimumab and adalimumab are humanized MABs; all three have inhibitory effects 
at both TNF locations. Certolizumab is an antibody fragment (FAB) that attaches to membrane-
bound as well as membrane-soluble TNF. All four are more effective in CrD than is etanercept.
In TRAPS, as etanercept is a soluble p75 kd receptor, it binds extracellular, soluble TNF 
unbound by dysfunctional p55 mutant receptors. Some TNFR1 mutations effect cysteine resi-
dues increasing risk of amyloidosis. Successful use of etanercept minimizes this complication 
[20, 46]. Etanercept may be beneficial in TRAPS patients but has a variable effect; other bio-
logic agents, especially IL-1 blockers, may be more beneficial [47]. Anti-TNF MABs such as 
infliximab may cause paradoxical increased inflammation due to varying effects on both TNF 
receptors. Infliximab is therefore not used in etanercept failures [23, 48, 49].
Anti-TNF therapy has a role in FMF in colchicine failures [27, 50]. Etanercept and MAB anti-TNF 
therapies have been reported to be of some benefit in these patients. Good clinical and biological 
responses suggest these agents are options for more resistant FMF cases to prevent amyloidosis.
4.3. Anti-IL-6 therapy
By binding to its cell surface receptor and subsequent activation of DAMPS, TLRs, and 
intracellular protein kinase signaling, IL-6 has been shown to be an important cytokine 
in the inflammatory cascade. Complex interactions exist between IL-1 and Il-6 regulatory 
pathways. IL-6 also stimulates the adaptive immune system through B cell immunoglobulin 
production, elevated inflammatory markers (C-reactive protein), and promotion of Th17 
cell maturation. Tocilizumab is a humanized MAB that blocks IL-6 signaling by adhering to 
membrane-bound IL-6 and its soluble receptors. This agent blocks downstream activation 
of adhesion molecules, osteoclasts, and maturation of both T and B cells [51]. As IL-6 is a 
key cytokine in RA, AOSD and systemic JIA (now thought to be part of the AutoIDx family), 
and inhibition of its function by tocilizumab has clinical benefit, this cytokine antagonist 
was approved by the FDA [52].
Immunotherapy - Myths, Reality, Ideas, Future280
Tocilizumab is not as effective in CAPS as anti-IL-1 inhibitors, with lack of response in 
NOMID possibly due to the extremely high IL-1 levels in this disease that requires more direct 
blockade of IL-1 that cannot be achieved through anti-IL-6 approaches. In TRAPS and FMF, 
several case reports detail clinical response to tocilizumab following inadequate response to 
etanercept; however, cytokine levels did not change appreciably [27, 49, 53, 54]. The benefit of 
anti-IL-6 therapy in other AutoIDx remains to be determined.
4.4. Interferons
Induced IFNs bind to IFN-α receptors on plasmadendritic cells. These cells upregulate many 
IFN-induced genes and are termed the “IFN signature” [55]. These gene products have inhib-
iting and/or activating effects on downstream immunologic activity. As a therapeutic agent, 
IFN-α has been used in hepatitis C and relapsing and remitting multiple sclerosis, an autoim-
mune neurologic disease. IFN-α therapy in colchicine-resistant FMF was reportedly beneficial 
but not confirmed in subsequent studies [27]. The IFN signature correlates with disease activ-
ity in autoimmune diseases and identifies response subsets. The IFN signature may also be 
important in the pathogenesis of subsets of AutoIDx, as well [56]. Treatments that inhibit IFN 
signaling pathways continue to be sought for the more common autoimmune diseases [11, 57, 58] 
which should then result in additional agents for study in AutoIDx.
4.5. Cytokine signaling
Strategies that employ cytokine receptor blockers or that provide decoys for soluble cyto-
kines have been reviewed above. Alternatively, reducing effects of cytokines can be achieved 
through interference with post-receptor intracellular downstream signaling pathways. As 
suggested above, targeting IFN pathways may be a successful approach for some AutoIDx. 
Recently, AutoIDx related to IFN dysregulation, the interferonopathies, have been identified. 
Normally, IFN binding to receptors exerts downstream effects through intracellular path-
ways via protein kinases. JAK-STAT signaling transmits extracellular information to nuclei 
influencing DNA transcription and increasing IFN and cytokine production. Tofacitinib is 
the first JAK inhibitor recently approved for treatment of RA. The AutoIDx SAVI is due 
to a mutation affecting STING membrane receptors leading to excessive IFN production. 
Overstimulation of downstream immunologic activity due to abnormally high levels of 
IFN-IFNAR binding can lead to increased signaling that can be blocked by tofacitinib JAK-
inhibition. In this way, overabundant downstream IFN effects are limited. Studies show 60% 
improvement in inflammation in vitro. Clinical trials in patients with this rare disorder are 
underway [2, 28].
5. Considerations in the use of immunotherapeutics
Some patients with AutoIDx have severe illnesses, and treatment is necessary to alleviate 
morbidity and prevent mortality. However, concerns regarding potential toxicity of immu-
notherapeutics must be addressed. Risks are present with all agents: infection, induction of 
carcinogenesis, autoantibody formation, and development of demyelination. Additionally, 
infusion or injection site reactions, as well as generally transient side effects, such as increased 
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liver function tests, decreased blood cell counts, and abnormalities in lipid profiles, have been 
attributed to these agents. Dose adjustments, premedication administration, and address-
ing concomitant risk factors often minimize side effects. Depending on concerns due to the 
patient’s underlying disease, toxicity fears may or may not take precedence in medication 
selection.
5.1. Infections
Immunotherapeutic agents all produce some degree of immunosuppression in addition to 
their disease controlling effects. Development of opportunistic infections with viruses, fungi, 
atypical bacteria, and prion associated complications (such as progressive multifocal leukoen-
cephalopathy) are potential concerns. FDA warnings advise against prescribing these drugs 
for patients with active infections including hepatitis C or B [51, 59]. Continued vigilance by 
patients and assessment by health care providers for any possible infectious complication is 
necessary when using immunotherapeutic agents.
Given concerns about risk of reactivation of tuberculosis (MTB), all patients are screened for 
MTB prior to starting biologic therapies [60, 61]. MTB confinement in granulomas requires 
normal CD8+ T cells and TNF activity; infliximab and biologics that effect receptor-bound 
TNF inhibit this function [62]. Little data exists regarding MTB risk for agents other than anti-
TNF drugs [61]; however, screening for MTB is requested for most patients prior to starting 
biologic therapy.
5.2. Neoplastic disease
Patients with RA, psoriatic arthritis, and CrD are at risk of developing disease-related malignan-
cies over their lives. The concern has been raised that biologic agents increase this risk. Large epi-
demiologic studies have not substantiated this concern for the most part. The rate of lymphoma 
in RA patients treated with biologic agents is similar to those who have never been treated. Those 
with prior cancer diagnoses are not at increased risk of recurrence [63, 64]. In 2008, a report from 
the FDA raised concerns about biologic agents and neoplastic disease in pediatric CrD and JIA 
patients. The pediatric rheumatology community worldwide has questioned this interpretation 
of JIA data [65]. Continued surveillance and monitoring of malignancies is crucial post-market-
ing for all biologic agents as the medical community, and patients remain vigilant regarding 
this important issue.
5.3. Demyelination
Studies using early anti-TNF-α agents in multiple sclerosis patients detected worsening dis-
ease, and trials were halted. The development of demyelinating toxicity in RA patients also 
has been reported. The mechanism of this side effect may be related to blocking effects on TNF 
receptor2 75 kd which is required for oligodendrocyte growth. Current anti-TNF therapies 
block TNFR2 75 kd as well as TNFR1 55 kd; the latter of which is linked more tightly to other 
autoimmune diseases as well as to TRAPS. Given that some anti-TNF blockers inhibit both 
receptors, improved control of inflammation may be met with worsening demyelination – an 
unacceptable trade-off. Future agents that selectively block TNFR1 55 kd might alleviate this 
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concern [11]. Current approaches include close monitoring all patients treated with anti-TNF 
agents for any concerning neurologic signs.
5.4. Human anti-chimeric antibody and autoantibody formation
In theory, more human-like MABs might be less immunogenic and less susceptible to human 
anti-chimeric antibody (HACA) formation [51, 66]. HACAs are thought to be responsible for 
side effects, interference with laboratory testing, as well as potential decrease in efficacy of 
these therapies. Decreased response to treatment due to HACAs has been of specific concern 
following the use of certain agents, such as infliximab in CrD and RA [67, 68]. Patients who 
developed anti-infliximab HACAs are also more likely to have infusion reactions and pos-
sibly reduced therapeutic benefit. Awareness of the risk of HACA formation and its conse-
quences is crucial information for prescribing clinicians [69, 70].
Autoantibody formation in patients receiving immunotherapeutic agents is well described 
[70]. Development of antinuclear antibodies (ANAs) is reported in patients in biologic trials. 
HACAs may produce false-positive autoantibody results due to interference in laboratory 
tests [70]. Autoimmune syndromes have been triggered by the use of immunotherapeutic in 
patients with RA and, in theory, also may develop in similarly treated patients with AutoIDx 
[51, 71]. One must be aware of the potential for these agents to cause false-positive autoanti-
bodies or to trigger onset of autoimmunity. These concerns must be recognized by patients 
and be part of surveillance by practitioners caring for individuals on biologics.
5.5. Selection of immunotherapeutics
Immunotherapeutic agents currently available are often administered parenterally. 
Intravenous and self-injected formulations of these agents are typically prescribed for 
patients. Infusion medications tend to be even more expensive due to nursing and infusion 
center costs in addition to the price of the drug itself, making treatment cost prohibitive for 
some patients. Studies also show that patient preferences regarding medication choices (oral 
versus injection versus infusion therapy) often do not coincide with providers’ intuition about 
patient choices. Access to medical care, attentive nursing, insurance coverage and cost are key 
factors for patients’ choice of therapy [72]. “Biosimilar” generic-type biologic agents are soon 
coming to the US market with estimated savings of 20–35% off name-brand charges. These 
agents will be economically advantageous to insurers and patients, assuming these “similar” 
medications are truly as effective as name-brand biologic agents [73]. These less expensive 
immunotherapeutics could potentially be accessed by more patients, improving disease con-
trol for a greater number of afflicted individuals.
6. Future directions/outlook
Safe and effective treatment options are the goals of biologic drug development and utiliza-
tion. In the future, scientific advances in precision medicine and next-generation sequencing 
will enable precise identification of disease phenotypes/genotypes to predict response to and 
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toxicity from biologic agents for autoimmune diseases [74, 75]. This advance will increase our 
ability to tailor immunotherapeutic selection for those with AutoIDx to target recognized con-
sequences of genetic mutations. As knowledge about autoinflammation continues to expand, 
new and more directed therapies will be trialed and utilized to treat these rare disorders. In 
this era of the “triple aim” in patient care, attention to patient experience, improving popula-
tion health, and minimizing complications of disease and treatment, including cost, one can 
predict that the outlook for this population with rare genetic inflammatory diseases will be 
much brighter with greater opportunities for them to be treated with disease-specific and tar-
geted therapies. Increasingly, these therapies have changed the lives of patients with AutoIDx 
in recent years and will be able to make even more of a difference in the future.
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